Ramanan Laxminarayan

Summary

Affiliation: Resources for the Future
Country: USA

Publications

  1. pmc Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty
    David L Smith
    Emerging Pathogens Institute and Department of Biology, University of Florida, Gainesville, 32611, USA
    Malar J 9:217. 2010
  2. doi request reprint Should new antimalarial drugs be subsidized?
    Ramanan Laxminarayan
    Resources for the Future, USA
    J Health Econ 29:445-56. 2010
  3. doi request reprint A global subsidy: key to affordable drugs for malaria?
    Ramanan Laxminarayan
    Resources for the Future, Washington, D C, USA
    Health Aff (Millwood) 28:949-61. 2009
  4. doi request reprint Global investments in TB control: economic benefits
    Ramanan Laxminarayan
    Resources for the Future, Washington, D C, USA
    Health Aff (Millwood) 28:w730-42. 2009
  5. pmc Clinically immune hosts as a refuge for drug-sensitive malaria parasites
    Eili Y Klein
    Resources for the Future, 1616 P St, NW, Washington, DC 20036, USA
    Malar J 7:67. 2008
  6. ncbi request reprint Advancement of global health: key messages from the Disease Control Priorities Project
    Ramanan Laxminarayan
    Resources for the Future, 1616 P Street NW Suite 600, Washington, DC 20036, USA
    Lancet 367:1193-208. 2006
  7. ncbi request reprint Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?
    Ramanan Laxminarayan
    Resources for the Future in Washington, DC, USA
    Health Aff (Millwood) 25:325-36. 2006
  8. ncbi request reprint On the implications of endogenous resistance to medications
    Ramanan Laxminarayan
    Resources for the Future, Washington, DC 20036, USA
    J Health Econ 21:709-18. 2002
  9. ncbi request reprint Tobacco initiation, cessation, and change: evidence from Vietnam
    Ramanan Laxminarayan
    Resources for the Future, Washington, DC 20036, USA
    Health Econ 13:1191-201. 2004
  10. ncbi request reprint Act now or later? Economics of malaria resistance
    Ramanan Laxminarayan
    Resources for the Future, Washington, District of Columbia 20036, USA
    Am J Trop Med Hyg 71:187-95. 2004

Detail Information

Publications26

  1. pmc Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty
    David L Smith
    Emerging Pathogens Institute and Department of Biology, University of Florida, Gainesville, 32611, USA
    Malar J 9:217. 2010
    ..Such strategies are deployed to best effect before resistance has emerged, under conditions of great uncertainty...
  2. doi request reprint Should new antimalarial drugs be subsidized?
    Ramanan Laxminarayan
    Resources for the Future, USA
    J Health Econ 29:445-56. 2010
    ..This paper develops a conceptual and numerical framework for understanding the conditions under which subsidies for artemisinin combinations can be justified on economic efficiency grounds...
  3. doi request reprint A global subsidy: key to affordable drugs for malaria?
    Ramanan Laxminarayan
    Resources for the Future, Washington, D C, USA
    Health Aff (Millwood) 28:949-61. 2009
    ..If artemisinins are priced more competitively, resistance to them will be delayed...
  4. doi request reprint Global investments in TB control: economic benefits
    Ramanan Laxminarayan
    Resources for the Future, Washington, D C, USA
    Health Aff (Millwood) 28:w730-42. 2009
    ..Benefit-cost ratios of sustaining DOTS at current levels relative to having no DOTS exceeded 1 in all twenty-two high-burden, TB-endemic countries and sub-Saharan Africa...
  5. pmc Clinically immune hosts as a refuge for drug-sensitive malaria parasites
    Eili Y Klein
    Resources for the Future, 1616 P St, NW, Washington, DC 20036, USA
    Malar J 7:67. 2008
    ..This model reconsiders the role of immunity in the dynamics of malaria transmission and its impact on the evolution of antimalarial drug resistance under the assumption that immune individuals are infectious...
  6. ncbi request reprint Advancement of global health: key messages from the Disease Control Priorities Project
    Ramanan Laxminarayan
    Resources for the Future, 1616 P Street NW Suite 600, Washington, DC 20036, USA
    Lancet 367:1193-208. 2006
    ..DCP2 also examines crosscutting issues crucial to the delivery of quality health services, including the organisation, financial support, and capacity of health systems. Here, we summarise the key messages of the project...
  7. ncbi request reprint Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?
    Ramanan Laxminarayan
    Resources for the Future in Washington, DC, USA
    Health Aff (Millwood) 25:325-36. 2006
    ..We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs...
  8. ncbi request reprint On the implications of endogenous resistance to medications
    Ramanan Laxminarayan
    Resources for the Future, Washington, DC 20036, USA
    J Health Econ 21:709-18. 2002
    ..The paper shows that a mixed treatment policy of multiple drug use is generally desirable, and characterizes analytically the conditions under which it is optimal...
  9. ncbi request reprint Tobacco initiation, cessation, and change: evidence from Vietnam
    Ramanan Laxminarayan
    Resources for the Future, Washington, DC 20036, USA
    Health Econ 13:1191-201. 2004
    ..We find that higher cigarette prices may not necessarily encourage quitting and may only divert cigarette smokers to rustic tobacco, which is potentially as harmful to human health as cigarettes...
  10. ncbi request reprint Act now or later? Economics of malaria resistance
    Ramanan Laxminarayan
    Resources for the Future, Washington, District of Columbia 20036, USA
    Am J Trop Med Hyg 71:187-95. 2004
    ....
  11. ncbi request reprint Does reducing malaria improve household living standards?
    Ramanan Laxminarayan
    Resources for the Future, Washington DC 20036, USA
    Trop Med Int Health 9:267-72. 2004
    ..60 average improvement in annual consumption of all households, or a roughly dollars 180 million annual economic benefit in the form of improved living standards...
  12. pmc Benefits of using multiple first-line therapies against malaria
    Maciej F Boni
    Resources for the Future, Washington, DC 20036, USA
    Proc Natl Acad Sci U S A 105:14216-21. 2008
    ..The clinical benefits of using multiple first-line therapies against malaria suggest that MFT policies should play a key role in malaria elimination and control programs...
  13. doi request reprint Antibiotic resistance-the need for global solutions
    Ramanan Laxminarayan
    Center for Disease Dynamics, Economics and Policy, Washington, DC, USA Princeton University, Princeton NJ, USA Public Health Foundation of India, New Delhi, India
    Lancet Infect Dis 13:1057-98. 2013
    ..Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed. ..
  14. doi request reprint Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010
    Nikolay P Braykov
    Center for Disease Dynamics, Economics and Policy, Washington, DC 20036, USA
    Infect Control Hosp Epidemiol 34:259-68. 2013
    ..We examined national trends in the proportion of Klebsiella pneumoniae isolates resistant to carbapenems (CRKP) and third-generation cephalosporins (G3CRKP)...
  15. pmc Seasonal and temperature-associated increases in gram-negative bacterial bloodstream infections among hospitalized patients
    Michael R Eber
    Center for Disease Dynamics, Economics and Policy, Washington, DC, United States of America
    PLoS ONE 6:e25298. 2011
    ....
  16. pmc Superinfection and the evolution of resistance to antimalarial drugs
    Eili Y Klein
    Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08544, USA
    Proc Biol Sci 279:3834-42. 2012
    ..Considering superinfection in mathematical models of antimalarial drug resistance may thus be important for generating accurate predictions of interventions to contain resistance...
  17. pmc "One-size-fits-all"? Optimizing treatment duration for bacterial infections
    Patricia Geli
    Center for Disease Dynamics, Economics and Policy, Washington, D C, United States of America
    PLoS ONE 7:e29838. 2012
    ..Adjusting drug treatment strategies to account for the impact of the differences in the ecological niche occupied by commensal flora relative to invasive bacteria could be effective in delaying the spread of bacterial resistance...
  18. doi request reprint Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012
    Larissa May
    Department of Emergency Medicine, George Washington University, Washington, DC, USA
    Antimicrob Agents Chemother 58:1404-9. 2014
    ....
  19. doi request reprint Incentives for reporting disease outbreaks
    Ramanan Laxminarayan
    Center for Disease Dynamics, Economics and Policy, Washington, D C, United States of America Princeton University, Princeton, New Jersey, United States of America Public Health Foundation of India, ISID Campus, Institutional Area, Vasant Kunj, New Delhi, India
    PLoS ONE 9:e90290. 2014
    ..However, reports can also bring medical assistance to contain the outbreak, including access to vaccines...
  20. doi request reprint Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia
    Michael R Eber
    Center for Disease Dynamics, Economics, and Policy, Resources for the Future, 1616 P Street NW, Washington, DC 20036, USA
    Arch Intern Med 170:347-53. 2010
    ..Reliable estimates of these costs are needed to efficiently target limited resources for the greatest public health benefit...
  21. ncbi request reprint Antimicrobial resistance in developing countries. Part II: strategies for containment
    Iruka N Okeke
    Department of Biology, Haverford College, Haverford, PA, USA
    Lancet Infect Dis 5:568-80. 2005
    ....
  22. ncbi request reprint Antimicrobial resistance in developing countries. Part I: recent trends and current status
    Iruka N Okeke
    Department of Biology, Haverford College, Haverford, PA, USA
    Lancet Infect Dis 5:481-93. 2005
    ..In part II, to be published next month, we will review potential containment strategies that could address this burgeoning problem...
  23. ncbi request reprint Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development
    Philippe J Guerin
    Norwegian Institute of Public Health, Norway
    Lancet Infect Dis 2:564-73. 2002
    ..Evidence on these approaches should provide national governments and international donors with the cost-benefit information that would justify much-needed increases in global support for appropriate and effective malaria control...
  24. ncbi request reprint Economic issues and antibiotic resistance in the community
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    Ann Pharmacother 36:148-54. 2002
    ..Multiple economic factors, at the level of physicians, patients, healthcare organizations, and pharmaceutical companies, foster poor antibiotic use...
  25. pmc Strategic interactions in multi-institutional epidemics of antibiotic resistance
    David L Smith
    Fogarty International Center, National Institutes of Health, Bethesda, MD 20892 2220, USA
    Proc Natl Acad Sci U S A 102:3153-8. 2005
    ..We conclude that regional coordination and planning for HIC is an essential element of public health planning for hospital-acquired infections...